๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA ยท Real-Time Price ยท USD
23.22
-1.08 (-4.44%)
At close: Nov 20, 2026, 4:00 PM EST
23.17
-0.05 (-0.22%)
After-hours: Nov 20, 2026, 7:30 PM EST
โ† View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 9, 2026

Summary

DMR-001 is in global Phase I development for ET and MF, with pan-mutant activity, longer half-life and less-frequent dosing as intended differentiators. Proof-of-concept readouts are expected from mid-2027, and Phase III is anticipated to start in mid-2028.

Rosy Liao
Analyst, Guggenheim Securities

Good afternoon, everyone. Welcome to the last session of the day at our first day of the Guggenheim Healthcare Innovation Conference. My name is Rosy Liao, member of the biotech research team here at Guggenheim Securities. With me, I have the team at Damora Therapeutics, Becker Hewes, Chief Medical Officer, and Sherwin Sattarzadeh, Chief Operating Officer. Great to have you here with me. For those in the audience who are maybe less familiar with the story, could you just start with a quick overview of the company and maybe give a high-level view of where you guys are at today across the pipeline?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Sure. Thanks, Rosy, for having us here today. Hi, everyone. Before I get started, we're going to be making some forward-looking statements, so refer everyone to our latest SEC filings for risk factors and other information. My name is Sherwin Sattarzadeh. I'm the Chief Operating Officer at Damora. Becker Hewes, Chief Medical Officer. We worked together at Blueprint Medicines before this, working on bringing an important medicine to market in the hematology space. Damora is in the MPN space. We are advancing a portfolio of potential best-in-class antibodies for the treatment of essential thrombocythemia and myelofibrosis, both of which are severely debilitating diseases. I think many people know about myelofibrosis, which causes the bone marrow fibrosis leading to reduced overall survival, and ET is a very serious disease that comes with the risk of thrombosis and hemorrhage, and the risk of progression to myelofibrosis.

DMR-001 is our lead asset and is an Fc-null antibody that is a pan-mutant inhibitor with a long-lasting half-life that compares favorably against the lead competitor molecule in the space at the moment that has completely or significantly de-risked the biology, and we are looking to advance our program forward in those two indications. MPNs are a very large market opportunity with over a $5 billion U.S. opportunity alone. We'll talk a little bit about the prevalence of the different mutCALR mutations, but this is about a 45,000 patient population in the U.S. that currently does not have any symptom, any disease-modifying therapies, and really the therapies right now are just symptomatic improvement agents. We've recently started our phase I study. It's called CLARITY-101. It'll be a global study.

It's in the U.S. and Australia already, and we'll be rolling out more broadly beyond that, and we're looking to very rapidly move this DMR-001 through dose escalation and into expansion to bring it to patients with both type one and non-type one patients that are waiting for this therapy. Lastly, I'll just say we have $530 million in cash and have built a team of highly experienced hematology oncology drug developers, and we'll be moving the program quickly towards phase III, which we anticipate starting in mid 2028.

Rosy Liao
Analyst, Guggenheim Securities

Great. That was a great opener. Maybe just kind of double-click on the mutCALR opportunity, which you kind of alluded to already. Obviously, the space has become one of the more exciting targets in MPNs over the past year. I guess you kind of talked about this, but how do you think about the size and the shape of the opportunity across both ET and MF, and where do you see the greatest unmet need?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah. Myelofibrosis therapies have been around for some time, about 10, 15 years now, and generate billions of dollars worldwide. These are primarily JAK-directed therapies, and there have not been disease-modifying therapies for mutCALR patients. After JAK, mutCALR makes up the next largest group of patients, with about 25% of ET patients having a CALR mutation and about 35% of MF patients, amounting to about 45,000 patients worldwide. The current therapy, our lead competitor, Incyte 989, has really de-risked the biology in the space and has demonstrated that an Fc-null targeting agent in looking at mutCALR is a viable path to treating these patients. Unfortunately, the activity of that agent right now is really in the type one patients and less so in the none-type one patients, as well as its limitations on its PK profile, its high dose, and frequent volume of route of administration.

We're looking to bring forward DMR-001 with an every four week subQ administration, pan-mutant activity, as we've recently talked about and we'll be talking about more as ASH data is presented, for the broader patient population.

Rosy Liao
Analyst, Guggenheim Securities

Great. That's a good segue into my next question, which is kind of diving a little bit deeper on DMR-001.

You will present new preclinical data at ASH on activity across the different mutant types. I guess, what should we take away from that dataset?

Sherwin Sattarzadeh
COO, Damora Therapeutics

I think what has been shown thus far is that the targeting of mutCALR with the Incyte molecule has clearly demonstrated that you can gain good activity for both ET and MF patients, and yet there is about 50% of the population who have the none-type one mutations that really are not seeing the same level of benefit as what DMR-001 can bring. What we have also done is improve the PK profile relative to what they have been able to show to have a much longer-lasting antibody that can be dosed far less frequently than 989 can.

Rosy Liao
Analyst, Guggenheim Securities

I guess, just kind of speaking to that longer half-life, I guess, how confident are you that what you have seen in preclinical studies will translate into humans, and what do you really need to see to kind of confirm that in the clinic?

Sherwin Sattarzadeh
COO, Damora Therapeutics

I mean, I think the preclinical data that 989 demonstrated is really playing out in the clinic as was originally expected. Their shorter half-life, their potency primarily on the type one molecule really gives us confidence that our preclinical profile will be able to address those limitations as we move it forward. What we want to see is particularly in the early part of the study is to see that translation of our PK profile, of our preclinical profile into the clinic. We will be looking at that activity across mutations. We will be looking for that validation of the PK half-life in humans, to really lend proof to the differentiation of this molecule.

Rosy Liao
Analyst, Guggenheim Securities

Great. When you dive into your trial, CLARITY-101, this trial is currently enrolling. You are planning for this to be a global trial, from what I understand. Can you just remind us where you are in terms of site activations and also with the global regulatory clearance? Can you also maybe just walk us through the design, and I guess, how quickly do you expect to reach a recommended dose for expansion?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah, I can start on that.

Rosy Liao
Analyst, Guggenheim Securities

Sorry, it is a very loaded question.

Sherwin Sattarzadeh
COO, Damora Therapeutics

Pass it to Becker. Yeah, as we disclosed last week, the IND has been cleared by the FDA. The study is ongoing in the U.S. and in Australia. We are planning for this study to be a global, large study. It is likely going to be the largest MPN study that has been conducted in phase I thus far. So we have 250 patients in the study, the protocol allows. We have a very interesting study design, a Bayesian escalation design that I will let Becker speak to.

Becker Hewes
Chief Medical Officer, Damora Therapeutics

Yeah, the study is designed to answer a lot of different questions and to really set us up to be able to start our pivotal studies as quickly as possible. This would be both for MF and for ET, and we will explore both single agent and, if necessary, combination with ruxolitinib. The significance of the Bayesian design is that it allows us to continue to explore doses as we expand in different parts of the disease. Imagine we have good evidence of efficacy and safety in ET, and we're still trying to understand the activity in myelofibrosis. Myelofibrosis takes a little bit longer to read out because you have to wait for a spleen scan and symptoms to resolve. We can go full bore into the expansion of the ET population as we continue to look at the myelofibrosis population.

That was an important thing to make sure that we kept speed going. Our starting dose, 100 mg, is within the therapeutic range. We don't expect this to be an extensive dose escalation. We expect to have to go through a few doses to better understand where the activity lies, but we really expect the escalation portion to just be setting up that expansion portion.

Rosy Liao
Analyst, Guggenheim Securities

Great. I believe you're also perhaps thinking about including patients who have previously seen a CALR antibody. Can you just walk us through kind of the rationale behind that process?

Becker Hewes
Chief Medical Officer, Damora Therapeutics

We've set up this trial to allow a very broad patient population, and that includes ET and MF, and even pre-fibrotic MF patients. This is to make sure that enrollment goes quickly and we get a full view of the efficacy across the spectrum of the indication. With respect to patients that have been on other agents before, as we said, the preclinical data should tell us what will happen in the clinic. We've got patients who may have been on 989 or may have been on the J&J T-cell engager, and we believe that DMR-001 will maintain or will have activity even where those agents do not have activity.

With respect to 989, even in type one, if you can imagine a patient with myelofibrosis, they've got marrow with a lot of fibrosis in there, having the intermittent therapy that 989 brings may not either get them as deep a response as they can have or maintain that response for a long period of time. Then certainly for patients with a type two mutation, we believe that the preclinical data indicates a much higher level of activity for DMR-001, so it would be logical to be able to put those patients that had been on 989 onto DMR-001.

The T-cell engagers, I think the response rate that we saw in the ET population with the J&J agent wasn't quite as deep as we expected it to be, there is room for improvement upon that, and we think DMR-001 can bring that to bear.

Rosy Liao
Analyst, Guggenheim Securities

Great. You've guided to two clinical proof of concept readouts beginning in mid 2027. I guess, as we head into that catalyst, there's been a lot of discussion just about endpoints recently, especially with Incyte starting their phase III trials. I guess, what are your thoughts on kind of which endpoints will matter the most, and your thoughts on maybe the composite endpoints, and how much weight will you put on kind of molecular markers such as allele burden?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Maybe we'll start with ET for a second. Really watching how Incyte has developed the primary endpoint for that study, or primary and secondary endpoints for that study, we're really happy with that. Having gotten to a place with the FDA where they can introduce VAF as a key secondary endpoint with obviously complete hematologic response as a primary endpoint, agreeing on a 24 week duration for that endpoint, that's a really great outcome, and we'll probably be looking at mirroring something like that in the ET side of it. On the myelofibrosis side, again, very much happy to have them in conversations with the FDA about evolving beyond SVR and TSS50 and trying to get things like VAF or transfusion independence into endpoints for myelofibrosis. Of course, we know for a second-line study, they've landed on SVR and TSS.

Interestingly, they need to account for the type one, none-type one activity, and so prioritizing the type one analysis there. But again, allowing for some continued dialogue that they're going to have in the frontline setting, we'll see what their ASH data, as they've alluded to, a little bit more mature later data cut coming out at ASH, to see what that frontline data looks like and how the activity between type one, none-type one fares in that earlier line setting, as well as potentially looking at combination versus monotherapy and how those factor into a phase III study design.

We'll see how this continues to evolve, but nice to see that they're landing in a place where they can potentially demonstrate benefit with those study designs, as well as just the creativity of going with a 36-week endpoint instead of 24 weeks, allowing for the mutCALR TSS to mature over time.

Rosy Liao
Analyst, Guggenheim Securities

Great. And maybe turning to your own dataset that you'll have next year, I guess, what do you think of as kind of the benchmark or the bar that you need to show for your readouts? And there's been some discussion recently just on how that mutCALR patients might do maybe a little bit worse on the traditional endpoints compared to what we've seen for Jakafi and the COMFORT studies. I guess, does that align with how you're thinking about it as well?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Hmm. Yeah. As we look into data disclosures next year with the study progressing through dose escalation, we're really going to be looking for the translation of that preclinical profile into the clinic, looking for the pan-mutant activity, as well as some of the early signals that we can expect for the translation of the PK profile into human half-life. If you think about the maturation of the datasets and the time points at which disease assessments are done between ET and MF, you can think perhaps some earlier dataset will be more indicative, more reflective of those earlier disease readouts. And then, what was the second part of your question?

Rosy Liao
Analyst, Guggenheim Securities

Oh, just on the mutCALR patients maybe doing a little bit worse.

Sherwin Sattarzadeh
COO, Damora Therapeutics

I think Incyte certainly has alluded to that several times. If you look at their EU label for Jakafi, it certainly speaks to the SVR rate being lower in the non-JAK2 mutated patients. Again, that just helps understand the type of phase III study you are going to have to run and the size of that study as you try to demonstrate much better SVR rates in the CALR patients. As we are starting to see with the type one patients that 989 has demonstrated in both frontline and second line, it is the none-type one patients that we are looking to show significantly better improvement on their outcomes with DMR-001.

Rosy Liao
Analyst, Guggenheim Securities

Great. I guess, as we are talking about your development plans here, I guess, could you maybe just walk us through what your general strategy is and how you are prioritizing the different indications? I guess, I think you also mentioned that potentially lower-risk patients could also be a meaningful opportunity for you. Can you just maybe walk us through your thought process there?

Sherwin Sattarzadeh
COO, Damora Therapeutics

In the phase I study, we are not prioritizing one population over the other. Both ET and MF patients will be able to are going to be part of the dose escalation, and then we will have population-specific expansions from there. Certainly not looking to prioritize one population over the other. I think, again, as you see the maturation of the data, ET platelet counts are sort of an earlier readout than the endpoints you have in myelofibrosis. But again, our anticipation, our expectation is to take DMR-001 forward in both populations. In terms of which lines of therapy we take them forward in, it is going to depend on the data and how that matures.

Rosy Liao
Analyst, Guggenheim Securities

Great. Then, I guess going back to the lower-risk population, is that something that you're interested in developing in?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah. I mean, the way we kind of think about it is the Fc-null approach, Fc-null mutCALR antibody, it should be the backbone of lifelong treatment for these patients. When we look at a patient who is early line versus post-prior therapies, there's really no reason to think that you wouldn't want to treat that patient with a targeted anti-mutCALR agent. When we speak with our physicians and KOLs, there's clearly an interest in driving the use of these agents earlier and earlier in the course of the disease, rather than waiting until patients are a little bit more advanced. Absolutely, we'll be looking at those earlier patients.

Rosy Liao
Analyst, Guggenheim Securities

Great. We've been talking about just 989's data a lot. I guess, they're expecting more data at ASH. As we kind of see more data from that program, what questions do you think they're answering for the class versus what do you think that you will need to answer for yourself?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah. I think certainly they've demonstrated the type one activity on the ET. We need to demonstrate the activity on the remaining patient population, which is about half the population. So, we're certainly going to be looking to answer that question. I think outstanding question on the myelofibrosis side of things still continues to be monotherapy versus combination. What is the additive effect of combining a anti-mutCALR agent with a JAK inhibitor? I think we can also think perhaps beyond ruxolitinib, and are there other JAK inhibitors that would make sense for us to study in combination? Then really to see sort of how that with the type one, none-type one kind of come together to understand what the registration study for registration program for DMR-001 could look like.

Rosy Liao
Analyst, Guggenheim Securities

Great. Makes sense. Earlier we talked about kind of the overall size of the market. I guess, how do you think of DMR-001's opportunity in a market where we could potentially have multiple options approved?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah, that's a good question. Again, I think when we look at the different sort of modalities that are available here, the Fc-null, effective and safe sort of modality should become the backbone of lifelong therapy for patients with these diseases. When we look at sort of what other constructs there may be, we look at J&J's TCE data that recently came out, as Becker was saying, you get some of the safety effects as expected with the TCE, but you're not really seeing the upside on the efficacy side of things.

What that does for our portfolio is we also have DMR-002, and we can look at the sort of bringing in a little bit more of the immune activation rather than just the signal blockade you get with the Fc-null approach, but as well as the signaling blockade that you don't get with the TCE approach. DMR-002 kind of gives us another tool in the arsenal of treatment for these patients. As we look beyond our portfolio and what's coming behind us, we really don't see a dataset that's meaningfully differentiated from what DMR-001's already bringing.

The step change from 989 to DMR-001, we talk about the none-type one activity, we talk about PK, the convenience, the volume of administration, route of administration, and then we look at what's coming behind in the next set of compounds, and you don't see that same differential improvement over what DMR-001's bringing. Really like where we're positioned right now with our portfolio.

Rosy Liao
Analyst, Guggenheim Securities

Great. You mentioned DMR-002. We also have DMR-003. Can you maybe just walk us through the rationale behind pursuing mutCALR from these three different angles, and I guess, maybe just elaborate a little bit more on where you really see all three of them fitting, whether the Fc-null, Fc-enhanced, or the bispecific?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yep. DMR-001's our lead program. We will be prosecuting that across the different patient populations we've been talking about. The great advantage we have is that DMR-002, we're going to file that application to regulators this quarter, and that'll be in the clinic in the first half of next year. So we'll have DMR-001 and DMR-002 in the clinic at the same time, and can really start to understand what a more potent Fc-null antibodies can do for the broad spectrum of patients, and then where is there still a need for perhaps more severe patients, and where an Fc-enhanced antibody can work, or if you need a TCE as well. I think the data that we saw from ET, from the J&J TCE in ET, leaves some questions still. We haven't seen the myelofibrosis dataset yet.

So as the data matures, we have the option to build a TCE that kind of addresses whatever limitations that the other TCEs currently have.

Rosy Liao
Analyst, Guggenheim Securities

As you mentioned, perhaps reserving the DMR-002, the Fc-enhanced molecule for more severe patients, is that something that you think will be limited to severe patients, or could that potentially be applicable to a broader population over time?

Sherwin Sattarzadeh
COO, Damora Therapeutics

I think time will tell. Again, the advantage of having both in the clinic is going to be that as the data matures from, or data emerges from one, informs the development of the other, and vice versa. I don't think at the moment we need to define exactly where it's going to play. What we do know is that given the safety profile we're seeing with the Fc-null approach, given the anticipated pan-mutant activity we want with DMR-001, it sort of becomes the mainstay of treatment for patients for the long term, and then we'll see where DMR-002 and DMR-003 are needed.

Rosy Liao
Analyst, Guggenheim Securities

Great. You mentioned at the beginning your cash balance. How are you thinking about prioritizing investment across the pipeline as each kind of move forward?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah. We're in the fortunate position of having about $530 million in cash. We are rapidly scaling the organization to prosecute against our ambitious goals. The way that that shows up currently is that we don't have to gate certain investments. We can move things quickly. We're already thinking about what our phase III studies could look like. We're accelerating our activities to develop an auto-injector, to have that ready to go as early as possible, and moving multiple programs forward in parallel. We don't really need to prioritize today against those things. DMR-001's going to go as fast as possible, DMR-002 will be in the clinic, and then as these data emerge, we'll understand exactly where we're going to play with each of them.

Rosy Liao
Analyst, Guggenheim Securities

Great. Longer term, is business development something you would consider, whether bringing in new assets or maybe partnering out some of your own programs?

Sherwin Sattarzadeh
COO, Damora Therapeutics

Yeah. I think with our background in hematology drug development, with the team that we are building, we certainly want to look beyond mutCALR in terms of what our portfolio is going to look like. We engage with others. We are searching for assets that could round out our portfolio on the heme side as well, sorry, on the MPN side, and then more broadly on heme as the organization matures.

Rosy Liao
Analyst, Guggenheim Securities

Great. I think that is all we had for today. Becker and Sherwin, thank you so much for joining us again.

Sherwin Sattarzadeh
COO, Damora Therapeutics

Thank you.

Becker Hewes
Chief Medical Officer, Damora Therapeutics

Thank you.